PT - JOURNAL ARTICLE AU - Cárdenas, Carmen M. Hernández AU - Sotelo, Carlos Torruco AU - Jurado, Felipe AU - Serna-Secundino, Héctor AU - Aguilar, Cristina AU - García-Olazarán, José G. AU - García, Diana Hernández AU - Goytia, Gustavo Lugo TI - Clinical characteristics and outcomes of patients with COVID-19 and ARDS admitted to a third level health institution in Mexico City AID - 10.1101/2020.09.12.20193409 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.12.20193409 4099 - http://medrxiv.org/content/early/2020/09/14/2020.09.12.20193409.short 4100 - http://medrxiv.org/content/early/2020/09/14/2020.09.12.20193409.full AB - Background In December 2019, the first cases of severe pneumonia associated with a new coronavirus were reported in Wuhan, China. Severe respiratory failure requiring intensive care was reported in up to 5% of cases. There is, however, limited information available in Mexico.Objectives The purpose of this study was to describe the clinical manifestations, and outcomes in a COVID-19 cohort attended to from March to May 2020 in our RICU. In addition, we explored the association of clinical variables with mortality.Methods The first consecutive patients admitted to the RICU from March 3, 2020, to Jun 24, 2020, with confirmed COVID-19 were investigated. Clinical and laboratory data were obtained. Odds ratios (ORs) were calculated using a logistic regression model. The survival endpoint was mortality at discharge from the RICU.Results Data from 68 consecutive patients were analyzed. Thirty-eight patients survived, and 30 died (mortality: 44.1 %). Of the 16 predictive variables analyzed, only 6 remained significant in the multivariate analysis [OR (95% confidence interval)]: no acute kidney injury (AKI)/AKI 1: [.61 (.001;.192)]; delta lymphocyte count: [.061 (.006;.619)]; delta ventilatory ratio: [8.19 (1.40;47.8)]; norepinephrine support at admission: [34.3 (2.1;550)]; body mass index: [1.41 (1.09;1.83)]; and bacterial coinfection: [18.5 (1.4;232)].Conclusions We report the characteristics and outcome of patients with ARDS and COVID-19. We found six independent factors associated with the mortality risk: delta lymphocyte count, delta ventilatory ratio, BMI, norepinephrine support, no AKI/AKI 1, and bacterial coinfection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: noneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were granted exemption by the hospital institutional review boards. The requirement for informed consent was also waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are available under request to the author https://drive.google.com/file/d/1ShZifyMwgC36Hal_X7mBcHdTVpPNJVVH/view?usp=sharing